Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic benefit, or even increased toxicity. Unfortunatel...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchiyama, Angel A. T., Silva, Pedro A. I. A., Lopes, Moisés S. M., Yen, Cheng T., Ricardo, Eliza D., Mutão, Taciana, Pimenta, Jefferson R., Machado, Larissa M., Shimba, Denis S., Peixoto, Renata D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985775/
https://www.ncbi.nlm.nih.gov/pubmed/33546228
http://dx.doi.org/10.3390/curroncol28010076
Descripción
Sumario:Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic benefit, or even increased toxicity. Unfortunately, only scarce data exist regarding the safety of concomitant PPI use with anti-cancer agents. We aim at reviewing current evidence on this possible interaction by dividing anti-cancer agents by class. Until further data is available, we encourage healthcare providers to limit unnecessary PPI overuse.

Ejemplares similares